Long‐term survival of children with acute non‐lymphoblastic leukemia

Odom, Lorrie F.; Morse, Helvise G.; Tubergen, David G.; Blake, Marilyn

doi:10.1002/mpo.2950160405

Cited by 7 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Repeat BCG vaccinations in longstanding T1D lower blood sugars in clinical trials ( Faustman et al., 2012 ; Kühtreiber et al., 2018 ). Lastly, the BCG vaccine has been used globally for the past 40 years to treat bladder cancer and, more recently, to treat lymphoma and lung cancer ( Babjuk et al., 2017 ; Davignon et al., 1971 ; Morales et al., 1976 ; Odom et al., 1988 ; Salmon et al., 2019 , 2020 ; Usher et al., 2019 ).…”

Section: Introductionmentioning

confidence: 99%

Bacillus Calmette-Guerin 's beneficial impact on glucose metabolism: Evidence for broad based applications

et al. 2021

View full text Add to dashboard Cite

Summary Bacillus Calmette-Guerin (BCG) vaccinations improve glycemic control in juvenile-onset Type I diabetes (T1D), an effect driven by restored sugar transport through aerobic glycolysis. In a pilot clinical trial, T1D, but not latent autoimmune diabetes of adults (LADA), exhibited lower blood sugars after multidose BCG. Using a glucose transport assay, monocytes from T1D subjects showed a large stimulation index with BCG exposures; LADA subjects showed minimal BCG-induced sugar responsiveness. Monocytes from T1D, type 2 diabetes (T2D), and non-diabetic controls (NDC) were all responsive in vitro to BCG by augmented sugar utilization. Adults with prior neonatal BCG vaccination show accelerated glucose transport decades later. Finally, in vivo experiments with the NOD mouse (a T1D model) and obese db/db mice (a T2D model) confirm BCG's blood-sugar-lowering and accelerated glucose metabolism with sufficient dosing. Our results suggest that BCG's benefits for glucose metabolism may be broadly applicable to T1D and T2D, but less to LADA.

show abstract

Section: Introductionmentioning

confidence: 99%

Bacillus Calmette-Guerin 's beneficial impact on glucose metabolism: Evidence for broad based applications

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Virtually all children with acute leukemia have complete remissions with initial therapy, with median survivals routinely exceeding five years, and many children seem to be cured 2,3 . This is true even for acute nonlymphoblastic leukemia in children 4 and is a remarkable contrast to the outlook for children before multiagent therapy became standard 20 years ago.…”

mentioning

confidence: 99%

Survival in Acute Leukemia in Elderly Patients

Whitely

Hannah

Holmes

1990

J American Geriatrics Society

View full text Add to dashboard Cite

Acute leukemia is more common in older people than in the young or middle-aged. However, the possibilities of achieving remission or prolonging survival are both inversely correlated with increasing age. We studied survival in 118 acute leukemia patients over the age of 64 seen at a university hospital from 1970 to 1987. Seventy percent had myeloid morphology. Median survival times were 106 days in those diagnosed in the 1970s and 71 days for those diagnosed in the 1980s. This was little changed from an earlier series from the same hospital extending back to the 1940s in which median survival was 69 days. Considering the two decades separately, age at diagnosis, sex, race, type of leukemia, and whether or not disease-specific treatment was applied had no significant effect on survival duration. Acute leukemia in the older patient demands difficult medical and ethical choices. Supportive therapy provides immediate comfort and relatively limited morbidity with certainty of death within a few months. Disease-specific therapy causes immediate morbidity for all, shortened life for the majority, and extended life for the minority.

show abstract

Fractionated total‐body irradiation preceding high‐dose cytosine arabinoside as a preparative regimen for bone marrow transplantation in children with acute leukemia

Kamani

Bayever

August

et al. 1995

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

Twenty children with acute leukemia between 3 and 19 years of age underwent allogeneic bone marrow transplantation from HLA-matched sibling donors after conditioning with total-body irradiation (1,200 cGy in six fractions of 200 cGy twice daily for 3 days) and high dose cytosine arabinoside (3 g/m2 given every 12 hours for 12 doses). Three patients died with acute toxicity. Six patients developed grade II acute graft versus host disease. With a median follow-up of 68 months (range 26-96 months), thirteen children (65%) are alive and in remission with Karnofsky scores of 90-100%. A patient with AML in resistant relapse went into remission but relapsed and died 5 months post-transplantation. Three other patients relapsed, 8, 12, and 16 months post BMT. Our results suggest that this conditioning regimen is associated with high but manageable acute toxicity and may be highly effective in controlling leukemia resistant to conventional chemotherapy.

show abstract

Long‐term survival of children with acute non‐lymphoblastic leukemia

Cited by 7 publications

References 45 publications

Bacillus Calmette-Guerin 's beneficial impact on glucose metabolism: Evidence for broad based applications

Bacillus Calmette-Guerin 's beneficial impact on glucose metabolism: Evidence for broad based applications

Survival in Acute Leukemia in Elderly Patients

Fractionated total‐body irradiation preceding high‐dose cytosine arabinoside as a preparative regimen for bone marrow transplantation in children with acute leukemia

Contact Info

Product

Resources

About